The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Clinical, quality of life, and economic value of acromegaly disease control
Open accessAbstract
Although acromegaly is a rare disease, the clinical, economic and health-related quality of life (HRQoL) burden is considerable due to the broad spectrum of comorbidities as well as the need for lifelong management. We performed a comprehensive literature review of the past 12 years (1998–2010) to determine the benefit of disease control (defined as a growth hormone [GH] concentration <2.5 μg/l and insulin-like growth factor [IGF]-1 normal for age) on clinical, HRQoL, and economic outcomes. Increased GH and IGF-1 levels and low frequency of somatostatin analogue use directly predicted increased mortality risk. Clinical outcome measures that may improve with disease control include joint articular cartilage thickness, vertebral fractures, left ventricular function, exercise capacity and endurance, lipid profile, and obstructive apnea events. Some evidence suggests an association between controlled disease and improved HRQoL. Total direct treatment costs were higher for patients with uncontrolled compared to controlled disease. Costs incurred for management of comorbidities, and indirect cost could further add to treatment costs. Optimizing disease control in patients with acromegaly appears to improve outcomes. Future studies need to evaluate clinical outcomes, as well as HRQoL and comprehensive economic outcomes achieved with controlled disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
The Medical Cost of Undiagnosed Sleep Apnea
Kapur, V., Blough, D. K., Sandblom, R. E., Hert, R., de Maine, J. B., Sullivan, S. D., & Psaty, B. M. (1999) · Sleep · doi:10.1093/sleep/22.6.749 · Cited by 384
Cited by
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Self-citationExpert consensus document: A consensus on the medical treatment of acromegaly
Giustina, A., Chanson, P., Kleinberg, D., Bronstein, M. D., Clemmons, D. R., Klibanski, A., van der Lely, A. J., Strasburger, C. J., Lamberts, S. W., Ho, K. K. Y., et al. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.21 · Cited by 407
Self-citationColao, A., Grasso, L. F. S., Giustina, A., Melmed, S., Chanson, P., Pereira, A. M., & Pivonello, R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0071-6 · Cited by 396
Self-citationA Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Giustina, A., Barkan, A., Beckers, A., Biermasz, N., Biller, B. M. K., Boguszewski, C., Bolanowski, M., Bonert, V., Bronstein, M. D., Casanueva, F. F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz096 · Cited by 371
Self-citationMazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Metadata
- Authors
- Ben-Shlomo, A., Sheppard, M. C., Stephens, J. M., Pulgar, S., & Melmed, S.
- Venue
- Pituitary
- Published
- 2011-05-20
- Volume
- 14
- Issue
- 3
- Pages
- 284-294
- ISSN
- 1386-341X (ISSN-L)
- 1573-7403
- OpenAlex
- W2056901144
- Cited by
- 159
- References
- 2
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical, quality of life, and economic value of acromegaly disease control. https://app.cochat.ai/papers/10.1007/s11102-011-0310-7
- The paper
- Ben-Shlomo, A., Sheppard, M. C., Stephens, J. M., Pulgar, S., & Melmed, S. (2011). Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. https://doi.org/10.1007/s11102-011-0310-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.